| NRT | NRT+ | VR |
---|---|---|---|
Primary outcome: continuous abstinence at week 5–52 | |||
 Abstinence, n (%) | 23 (10) | 29 (12.4) | 36 (15.3) |
 OR (97.5 % CI) | REF | 1.28 (0.67–2.43) | 1.62 (0.87–3.01) |
 Unadjusted | |||
 Adjusted | REF | 1.34 (0.67–2.70) | 1.84 (0.94–3.58) |
Secondary outcome: 7-day point prevalence abstinence at week 52 | |||
 n (%) | 34 (14.8) | 43 (18.5) | 51 (21.7) |
 Unadjusted | REF | 1.31 (0.76–2.25) | 1.60 (0.94–2.70) |
 Adjusted | REF | 1.31 (0.79–2.37) | 1.84 (1.04–3.26)* |
Secondary outcome: continuous abstinence at week 5–22 | |||
 n (%) | 38 (15.8) | 59 (24.5) | 65 (27.1) |
 Unadjusted | REF | 1.51 (0.88–2.57) | 2.01 (1.20–3.36)** |
 Adjusted | REF | 1.67 (0.95–2.94) | 2.18 (1.25–3.80)** |
Secondary outcome: 7-day point prevalence at week 22 | |||
 n (%) | 38 (15.8) | 59 (24.5) | 65 (27.1) |
 Unadjusted | REF | 1.72 (1.04–2.85)* | 1.96 (1.20–3.23)** |
 Adjusted | REF | 1.87 (1.09–3.20)* | 2.09 (1.22–3.57)** |
Secondary outcome: continuous abstinence week 5–10 | |||
 n (%) | 72 (29.4) | 94 (38.7) | 98 (39.8) |
 Unadjusted | REF | 1.52 (1.00–2.30) | 1.58 (1.04–2.39)* |
 Adjusted | REF | 1.62 (1.03–2.56)* | 1.66 (1.04–2.63)* |
Secondary outcome: 7-day point prevalence at week 10 | |||
 n (%) | 65 (26.5) | 88 (36.2) | 97 (39.4) |
 Unadjusted | REF | 1.57 (1.03–2.41)* | 1.79 (1.17–2.73)** |
 Adjusted | REF | 1.65 (1.04–2.61)* | 1.89 (1.19–3.01)** |